Alcobra Ltd  

(Public, NASDAQ:ADHD)   Watch this stock  
Find more results for David B. Rosen�
5.32
-0.08 (-1.48%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.24 - 5.48
52 week 5.01 - 25.44
Open 5.40
Vol / Avg. 248,837.00/727,707.00
Mkt cap 73.64M
P/E     -
Div/yield     -
EPS -1.87
Shares 13.64M
Beta     -
Inst. own 33%
Nov 3, 2014
Q3 2014 Alcobra Ltd Earnings Release (Estimated) Add to calendar
Sep 11, 2014
Alcobra Ltd at Aegis Capital Corp Healthcare & Technology Conference
Sep 3, 2014
Alcobra Ltd at FBR & Co Inaugural Healthcare Conference
Aug 13, 2014
Alcobra Ltd at Canaccord Genuity Growth Conference
Aug 11, 2014
Q2 2014 Alcobra Ltd Earnings Call - Webcast
Aug 11, 2014
Q2 2014 Alcobra Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.76% -41.75%
Return on average equity -80.35% -43.84%
Employees 9 -
CDP Score - -

Address

Amot Investment Building 9th Floor, 2 Weizman St.
TEL AVIV-YAFO, 6423902
Israel
+972-7-22204661 (Phone)
+972-7-22204664 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Officers and directors

Aharon Schwartz Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Yaron Daniely President, Chief Executive Officer, Director
Age: 37
Bio & Compensation  - Reuters
Tomer Berkovitz Chief Financial Officer
Bio & Compensation  - Reuters
David C. Baker Chief Commercial Officer
Bio & Compensation  - Reuters
Daniel E. Geffken Director
Age: 57
Bio & Compensation  - Reuters
Ehud Moshe Gilboa Director
Age: 47
Bio & Compensation  - Reuters
Dalia Megiddo M.D. Director
Age: 61
Bio & Compensation  - Reuters
Howard B. Rosen Director
Age: 55
Bio & Compensation  - Reuters